CYTK
Price:
$56.19
Market Cap:
$6.63B
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activa...[Read more]
Industry
Biotechnology
IPO Date
2004-04-30
Stock Exchange
NASDAQ
Ticker
CYTK
According to Cytokinetics, Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -10.44. This represents a change of -14.64% compared to the average of -12.23 of the last 4 quarters.
The mean historical PE Ratio of Cytokinetics, Incorporated over the last ten years is -5.95. The current -10.44 PE Ratio has changed 17.46% with respect to the historical average. Over the past ten years (40 quarters), CYTK's PE Ratio was at its highest in in the December 2016 quarter at 17.22. The PE Ratio was at its lowest in in the September 2020 quarter at -116.40.
Average
-5.95
Median
-9.20
Minimum
-19.53
Maximum
29.50
Discovering the peaks and valleys of Cytokinetics, Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 271.42%
Maximum Annual PE Ratio = 29.50
Minimum Annual Increase = -373.53%
Minimum Annual PE Ratio = -19.53
Year | PE Ratio | Change |
---|---|---|
2023 | -15.31 | 49.78% |
2022 | -10.22 | -29.29% |
2021 | -14.46 | 77.00% |
2020 | -8.17 | 99.32% |
2019 | -4.10 | 26.66% |
2018 | -3.24 | 2.70% |
2017 | -3.15 | -110.68% |
2016 | 29.50 | -373.53% |
2015 | -10.78 | -44.78% |
2014 | -19.53 | 271.42% |
The current PE Ratio of Cytokinetics, Incorporated (CYTK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-13.33
5-year avg
-10.45
10-year avg
-5.95
Cytokinetics, Incorporated’s PE Ratio is greater than DICE Therapeutics, Inc. (-23.17), greater than Edgewise Therapeutics, Inc. (-26.57), greater than Karuna Therapeutics, Inc. (-29.52), greater than Dyne Therapeutics, Inc. (-10.53), less than Stoke Therapeutics, Inc. (-7.28), less than Pliant Therapeutics, Inc. (-4.16), greater than Revolution Medicines, Inc. (-17.46), less than Relay Therapeutics, Inc. (-2.41), less than Black Diamond Therapeutics, Inc. (-2.50), less than Arvinas, Inc. (-6.15), less than Terns Pharmaceuticals, Inc. (-5.57), less than Amylyx Pharmaceuticals, Inc. (-1.64), less than Acumen Pharmaceuticals, Inc. (-1.97), less than Inozyme Pharma, Inc. (-2.47), less than X4 Pharmaceuticals, Inc. (6.73), greater than Blueprint Medicines Corporation (-47.82),
Company | PE Ratio | Market cap |
---|---|---|
-23.17 | $2.27B | |
-26.57 | $3.33B | |
-29.52 | $12.60B | |
-10.53 | $2.94B | |
-7.28 | $721.41M | |
-4.16 | $841.00M | |
-17.46 | $9.98B | |
-2.41 | $994.26M | |
-2.50 | $183.34M | |
-6.15 | $1.81B | |
-5.57 | $605.41M | |
-1.64 | $424.83M | |
-1.97 | $160.71M | |
-2.47 | $241.54M | |
6.73 | $99.77M | |
-47.82 | $6.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cytokinetics, Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cytokinetics, Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cytokinetics, Incorporated's PE Ratio?
How is the PE Ratio calculated for Cytokinetics, Incorporated (CYTK)?
What is the highest PE Ratio for Cytokinetics, Incorporated (CYTK)?
What is the 3-year average PE Ratio for Cytokinetics, Incorporated (CYTK)?
What is the 5-year average PE Ratio for Cytokinetics, Incorporated (CYTK)?
How does the current PE Ratio for Cytokinetics, Incorporated (CYTK) compare to its historical average?